Nick Paul Taylor
Publishes 6 feeds
All News
All News
10 posts · contributor
Biopharma Business News
Biopharma Business News
10 posts · contributor
Biopharma Mergers & Acquisitions
Biopharma Mergers & Acquisitions
10 posts · contributor
Drug Delivery News
Drug Delivery News
10 posts · contributor
Drug Development News
Drug Development News
10 posts · contributor
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances
10 posts · contributor
Lately
Roche pours $750M into Oregon manufacturing plant as obesity push expands
Roche pours $750M into Oregon manufacturing plant as obesity push expands
Roche pours $750M into Oregon manufacturing plant as obesity push expands
Roche pours $750M into Oregon manufacturing plant as obesity push expands
All News ·
Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe’s early-stage IPO standout defies biotech’s derisking trend
All News ·
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
All News ·
Everything on this page was read from markup Nick Paul Taylor published — a rel="me" link, an h-card, or the feed’s own author element. Nothing was inferred from anywhere else. To correct or remove it, get in touch. Machine-readable: JSON